Resource Allocation in Translational Neuroscience Tom Insel, M.D. Director National Institute of Mental Health National Institutes of Health March 5, 2009.

Slides:



Advertisements
Similar presentations
Mental health strategy of the Medical Research Council (UK) Opportunities for European engagement and a role of FEAM European Parliament 22 nd March 2011.
Advertisements

PERSONALIZED MEDICINE: Planning for the Future You, Your Biomarkers and Your Rights.
Parkinson’s disease (PD) is one of the most common chronic progressive neurodegenerative diseases. PD has a prevalence of 1.2 million people in Europe.
The Challenges of Dissemination: Your Role in the Development of Addiction Medicine Specialists Margaret M. Murray, Ph.D. Director, Global Alcohol Research.
1. 2 Key Applications of Genetic and Genomic Testing (slide 1 of 2) Diagnosis of Disease: Whereby genetic or genomic tests are used to screen a patient.
Retreat Topics iPSC Opportunities in NIAMS Diseases Science Management Forum: Leveraging and Strategic Funding Collaborations Atopic Dermatitis Advancing.
NHLBI Strategic Visioning Process: Charting Our Future Together
Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia
Thomas R. Insel, M.D. Director, NIMH Rethinking Mental Illness: How Research Will Change Practice October 22, 2008.
NIMH Priorities in Mental Health Services & Intervention Research Denise Juliano-Bult, M.S.W. National Institute of Mental Health OBSSR SW SRI – July 2012.
1 Marsha Frankel, LICSW Clinical Director of Senior Services-JF&CS Ruth Grabel, MPA Program Specialist and Coordinator, Massachusetts Partnership on Substance.
Thomas R. Insel, M.D. Director National Institute of Mental Health 2/15/05 NIMH: Setting Priorities.
©2007 RALPH SNYDERMAN Third Annual Prospective Health Care Conference "Where are We Now?" Ralph Snyderman, MD Chancellor Emeritus, Duke University November.
 NIMH envisions a world in which mental illnesses are prevented and cured.
RTI-UNC EPC Issues Exploration Forum (IEF):. Serious Mental Illness Dan Jonas, MD, MPH.
University of Utah Department of Human Genetics The New Science of Addiction Louisa A. Stark, Ph.D. Director.
The Impact of the Human Genome Project on Public Health Practice
Thomas R. Insel, M.D. Director, NIMH 9/29/10 Neuroscience Research: Challenges and Opportunities.
Career Development in Translational Addiction Research
The NIH Roadmap for Medical Research
Pharmacogenomics: Implications for CNS Drug Development in the 21st Century Challenges for Development & Approval – Patient & Funding Agency Perspective.
Genomics Alexandra Hayes. Genomics is the study of all the genes in a person, as well as the interactions of those genes with each other and a person’s.
Institutes’ Areas of Interest. National Cancer Institute.
The Nature of Disease.
New Pathways, New Connections: Tobacco and Behavioral Health Frances M. Harding, Director SAMHSA’s Center for Substance Abuse Prevention National Conference.
Science for Global Health: Fostering International Collaboration Norka Ruiz Bravo,PhD Special Advisor to the Director National Institutes of Health U.S.
Evaluating the Effectiveness of the CTRC: Designing Quantitative and Qualitative Measures to Assess in Real Time the Value of the Center Mike Conlon, University.
Ohio Justice Alliance for Community Corrections October 13, 2011.
Where to focus? Horizon 2020 'Health, demographic change and wellbeing' Open Info Day -Horizon 2020 'Health, demographic change and wellbeing' Brussels,
Public/Private Partnerships in Neuroscience and The George & Ann Ryan Neuroscience Institute.
Applying Research on Evidence- Based Mental Health Practices in Real-World Settings Michael Schoenbaum, PhD Senior Advisor Division of Services and Intervention.
DataBrief: Did you know… DataBrief Series ● February 2013 ● No. 36 Medicare Beneficiaries With Severe Mental Illness and Hospitalization Rates In 2010,
June 11, IOM, Reducing Suicide, 2002 Statement of Task w Assess the science base w Evaluate the status of prevention w Consider strategies for studying.
Integrating Mental Health, Physical Health and Substance Use for low income Medi- Cal and Uninsured Populations in California ITUP Conference – Panel Discussion.
Improving care for people with intellectual disabilities across the life span The ACI Intellectual Disability Network: Maxine Andersson Agency for Clinical.
European Federation of Allergy and Airways Diseases Patients Associations Updates on Innovative Research for Allergy and Respiratory Disease in the European.
Global Alliance against Chronic Respiratory Diseases GARD/NCD Action Plan & 2011 UN Summit on NCDs Niels H. Chavannes MD PhD Associate.
Thomas R. Insel, M.D. Director, NIMH Recovery : How Research Will Change Practice June 13, 2008.
DataBrief: Did you know… DataBrief Series ● February 2013 ● No. 38 Medicare Spending for Beneficiaries with Severe Mental Illness and Substance Use Disorder.
NIH ROADMAP FOR MEDICAL RESEARCH RESEARCH TEAMS OF THE FUTURE.
Care Packages in Substance Misuse Treatment Development of MH Care Clusters: overview  Service users in MH, clinicians found: idiosyncratic referral pathways.
NAS/IOM Review of Rare Diseases Research and Orphan Products Development - USA Timothy Cote, M.D., MPH Director, Office of Orphan Products Development.
Larry Fricks Director of Appalachian Consulting Group Vice President of Peer Services, Depression and Bipolar Support Alliance (404)
Brandon A. Gaudiano, Ph.D. Warren Alpert Medical School of Brown University Butler Hospital Providence, Rhode Island.
Trend in diagnostic biochip development Eiichiro Ichiishi, M.D., Ph.D. Department of Internal Medicine International University of Health and Welfare Hospital.
Community Health. Something to think about...  What are the different agencies that provide for the community locally, nationally, and globally?
Priorities in Mental Health Services Research David Chambers, D.Phil. Chief, Services Research and Clinical Epidemiology Branch Division of Services and.
B. Keith English, M.D. Chair, Pediatrics & Human Development Pediatric Cross-Campus Retreat Child Health Research at MSU 11/6/15.
Update from the Division of Epidemiology, Services and Prevention Research Wilson M. Compton, M.D., M.P.E. Director, Division of Epidemiology, Services.
Inflammatory Bowel Diseases November 19, 2007 NCDD Meeting Chair: Daniel K. Podolsky, MD Vice Chair: Eugene B. Chang, MD.
The Family Tree of “General Pediatrics” Where is it Going? Thomas F. Boat, MD Professor of Pulmonary Medicine Cincinnati Children’s Hospital Medical Center.
Systemic change by streamlined innovation: personalised medicine Novembre 8, 2013.
The NIMH Research Domain Criteria Initiative (RDoC): A Framework for Psychopathology Research February 20, 2014 Jill Heemskerk, PhD Deputy Director, Division.
Institute For Safety, Compensation and Recovery Research Presentation to Safety Culture from the Regulators' Perspective Symposium Dr Andrea de Silva,
Medical and Health research in Norway – in brief Director Mari K. Nes 22 June 2006.
Moiz Bakhiet, MD, PhD, Professor and Chairman
TITIN ANDRI WIHASTUTI SCHOOL OF NURSING FACULTY OF MEDICINE
NISCHR Academic Health Science Collaboration Launch
GARD/NCD Action Plan & 2011 UN Summit on NCDs
Group on Neural Issues.
NIMH Update Christopher Sarampote, NIMH 2017 AADCAP Annual Meeting
Lurie Children’s Strategic Research Initiative: Perinatal Origins of Childhood Disease: Research and Prevention at the Maternal-Fetal Interface A DevSci.
Research Overview Jacqueline French, MD Chief Scientific Officer
Christopher Sarampote, PhD
Information for Network Providers
EPA Graphics AFMRD EPA TASK FORCE.
Psychiatric Disorders: Diagnosis to Therapy
Genetic mechanisms of schizophrenia – presentation of ERA-NET NEURON project SYNSCHIZ - Budisteanu Magdalena, Papuc Sorina-Mihaela, Sorin Riga, Dan Riga,
Psychiatric Disorders: Diagnosis to Therapy
Aaron Ritter MD Cleveland Clinic Lou Ruvo Center for Brain Health
Presentation transcript:

Resource Allocation in Translational Neuroscience Tom Insel, M.D. Director National Institute of Mental Health National Institutes of Health March 5, 2009

Two Types of Translation BenchBedside Pathophysiology Genomics Biomarkers New interventions Practice Public health interventions Real world relevance Services research Dissemination

Re-Thinking “Mental Illness” “Mental Illness” Mental disorders are brain disorders. Mental disorders are developmental disorders. Current treatments may be necessary but not sufficient for recovery. Mental disorders result from complex genetic risk plus experiential factors.

Pathways to Pathophysiology Meyer-Lindenberg & Weinberger, Nature Rev Neurosci, 2007

Developmental Disorder Gene Discovery Small Molecule Therapeutics Target Identification Cellular Pathology Mouse/Fly/Cell Models Reverse Translation – The Molecular Medicine Cycle Adapted from Mark Bear, 2008

Clinical observation Mechanism of action Animal studies Clinical Trial Psychiatric Medications Clinical trial Molecular pathophysiology Small molecule screening Genetic association Modern Drug Discovery Insel & Scolnick, 2005

NIMH Strategic Plan Strategic Objective #1: Promote Discovery in the Brain and Behavioral Sciences to Fuel Research on the Causes of Mental Disorders Strategic Objective #2: Chart Mental Illness Trajectories to Determine When, Where and How to Intervene Strategic Objective #3: Develop New and Better Interventions for Mental Disorders that Incorporate the Diverse Needs and Circumstances of People with Mental Illness Strategic Objective #4: Strengthen the Public Health Impact of NIMH-Supported Research

NIMH – The 4 P’s Predictive (Biomarkers, Early detection) Preemptive (Early intervention, prevent morbidity) Personalized (Individualized interventions) Participatory (Partnerships)

Public Health Impact: Early Mortality in Individuals with Major Mental Illness (MMI) Adapted from Colton and Manderscheid, 2006, Prev Chronic Dis Data from outpatient and inpatient clients diagnosed with MMI Average age at time of death : 56 years Increased likelihood of dying from suicide

NIMH Mission To transform the understanding and treatment of mental illnesses through basic and clinical research, paving the way for prevention, recovery, and cure.

Paving the Way for Prevention, Recovery, and Cure